Drug Trial Radar · NCT06087094
A Trial of HRS-7450 in Chinese Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Oct 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Oct 2023
Primary completion
Dec 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this First-in-Human study is to evaluate the safety and tolerability after single ascending doses of HRS-7450 given to healthy subjects, compared to placebo..
Conditions
- Cerebral Stroke
Interventions
HRS-7450 ;PlaceboDrug
HRS-7450 or Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AEs)Time frame: 8 +/- 1 days
- Physical examinationTime frame: 2 days
- Vital signsTime frame: 2 days
- 12-lead electrocardiogram (ECG)Time frame: 24 hours
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.